Dulaglutide: A Review in Type 2 Diabetes.
- Published in:
- BioDrugs, 2015, v. 29, n. 6, p. 407, doi. 10.1007/s40259-015-0143-4
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2015 AND VI 29 AND IP 6
Results: 7
1
2
The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders.
- Published in:
- BioDrugs, 2015, v. 29, n. 6, p. 365, doi. 10.1007/s40259-015-0147-0
- By:
- Publication type:
- Article
3
Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers.
- Published in:
- BioDrugs, 2015, v. 29, n. 6, p. 373, doi. 10.1007/s40259-015-0149-y
- By:
- Publication type:
- Article
4
A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade) in Healthy Subjects.
- Published in:
- BioDrugs, 2015, v. 29, n. 6, p. 381, doi. 10.1007/s40259-015-0150-5
- By:
- Publication type:
- Article
5
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
- Published in:
- BioDrugs, 2015, v. 29, n. 6, p. 389, doi. 10.1007/s40259-015-0151-4
- By:
- Publication type:
- Article
6
Acknowledgement to Referees.
- Published in:
- BioDrugs, 2015, v. 29, n. 6, p. 363, doi. 10.1007/s40259-015-0152-3
- Publication type:
- Article
7
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
- Published in:
- BioDrugs, 2015, v. 29, n. 6, p. 399, doi. 10.1007/s40259-015-0142-5
- By:
- Publication type:
- Article